The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in MiceElizabeth C. Townsend, Michelle A. Kelliher, Mark A. Murakami et al.|Cancer Cell|2016Cited by 304
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicityBenjamin L. Lampson, Jennifer R. Brown, Siddha Kasar et al.|Blood|2016Cited by 289
Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell TransplantationAlex F. Herrera, Philippe Armand, Matthew Mei et al.|Journal of Clinical Oncology|2016Cited by 187
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantationPhilippe Armand, Alex F. Herrera, Yi‐Bin Chen et al.|Blood|2019Cited by 187
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b studyMatthew S. Davids, Jennifer R. Brown, Haesook T. Kim et al.|The Lancet Haematology|2018Cited by 115